Strategies to reduce relapse risk post-transplant in AML
Charles Craddock, CBE, FRCP, FRCPath, DPhil, FMedSci, Queen Elizabeth Hospital Birmingham, Birmingham, UK, presents on the value of allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) and strategies to reduce relapse risk. Prof. Craddock discusses novel induction regimens that may increase the number of transplant-eligible patients, including in the Phase II PARADIGM trial (NCT04801797) and the upcoming QUIZZICAL study. He also discusses optimized conditioning in the COSI trial (ISRCTN12434060) and post-transplant maintenance in the Phase III AMADEUS (NCT04173533) and MO-TRANS (NCT05429632) trials. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
